Inclusion Criteria:

• Signed informed consent,
• Age > 18,
• Ejection fraction ≥ 50%,
• hospitalization for heart failure in the last 6 months and
• current NYHA Class II-IV symptoms, OR

• current NYHA Class III-IV symptoms and one of the following:

  1. ECG or echocardiographic evidence of moderate/severe left ventricular hypertrophy,
  2. chest x-ray evidence of pulmonary congestion

Exclusion Criteria:

• Probable alternative cause of symptoms (pulmonary disease, severe anemia, etc.)
• Prior documented LVEF < 40% or qualitative moderate or greater LV systolic dysfunction.
• Current indication for statin therapy
• Intolerance to statin therapy.
• Documented ischemic heart disease requiring lipid-lowering therapy (i.e. CAD, myocardial infarction, stroke)
• Evidence of significant myocardial ischemia on stress testing at screening visit.
• Evidence of hepatic abnormality (defined as liver enzymes > 2 times the upper limit of normal values).
• Uncontrolled hypertension (BP > 150/100)
• Significant valvular disease.
• Atrial fibrillation
• Known familial hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy.
• Restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease (i.e. amyloidosis, sarcoidosis, hemochromatosis).
• Cor pulmonale or other cause of right heart failure not related to LV dysfunction.
• Clinically significant pulmonary disease.
• Pericardial constriction or hemodynamically significant pleural effusion.
• Uncontrolled arrhythmia.
• Any systemic condition other than heart failure that may limit survival to less than 2 years.
• Advance renal disease (serum creatinine > 3.0 mg/dl or on dialysis)
• Known intolerance or allergy to HMG CoA reductase inhibitors
• Uncontrolled hyper- or hypothyroidism.
• Any subject characteristic that may interfere with study compliance, such as baseline dementia, substance abuse, history of non-compliance with medications or appointments.
• Prisoners or other vulnerable populations.
• Any woman of child-bearing age with a documented positive pregnancy test.
• Subject is receiving therapy with other investigational therapy or is participating in any other clinical trial.